Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.
- Author:
Cheolwon SUH
1
;
Won Seog KIM
;
Jin Seok KIM
;
Byeong Bae PARK
Author Information
- Publication Type:Multicenter Study ; Review
- Keywords: Lymphoma; KSH; Lymhoma working party; CISL
- MeSH: Antibodies, Monoclonal, Murine-Derived; Hematology; Humans; Insurance, Health; Korea; Lymphoma; Lymphoma, B-Cell; Rituximab
- From:Blood Research 2013;48(3):171-177
- CountryRepublic of Korea
- Language:English
- Abstract: The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequent in Korea and has tried to give favors for the Korean lymphoma patients. CISL has conducted more than 30 retrospective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 prospective trials have been being performed for diffuse large B-cell lymphoma, marginal zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial for advanced marginal zone lymphoma has led to use Rituximab containing chemotherapy with the re-imbursement of health insurance in Korea. The multi-center trials of the CISL with new therapeutic modalities will improve further the survival of lymphoma patients not only quantitatively but also qualitatively.
